Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT04422366 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

8000

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Vulvar Cancer
Vaginal Cancer
CIN1
CIN2
CIN3
VaIN1
VaIN2
VaIN3
Genital Wart
VIN 1
VIN 2
VIN 3
AIS

Interventions

BIOLOGICAL: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
BIOLOGICAL: GARDASIL®

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.